Valued at a market cap of $29.6 billion, San Diego, California-based DexCom, Inc. (DXCM) is a medical device company ...

StockNews.com lowered shares of DexCom (NASDAQ:DXCM – Free Report) from a buy rating to a hold rating in a research report report published on Saturday. A number of other analysts have also weighed in ...

QRG Capital Management Inc. grew its holdings in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 8.6% in the 3rd quarter, ...

Piper Sandler analyst Matthew O’Brien maintained a Buy rating on Dexcom ... Its products include DexCom G4 PLATINUM System, DexCom G5 Mobil, DexCom G6, and DexCom Share. Read More on DXCM ...

Mike Kratky, an analyst from Leerink Partners, reiterated the Buy rating on Dexcom ... Its products include DexCom G4 PLATINUM System, DexCom G5 Mobil, DexCom G6, and DexCom Share.

These recent developments come in the wake of DexCom's strategic partnership with Tandem Diabetes Care (NASDAQ:TNDM), with the t:slim X2 insulin pump software now supporting both DexCom G7 and G6 ...

Insulet ’s PODD robust execution to expand the Omnipod 5 platform globally is a tailwind. The company is also capitalizing on ...

I think you buy the stock. I can’t believe that it ... Among its flagship products are the Dexcom G6 and G7 integrated CGM systems, which play an important role in helping individuals monitor ...

Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes ... multiple factors based on a wide range of metrics before deciding whether to buy. Like the Value Grade, AAII’s A+ ...